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Abstract
Prions arise when the cellular prion protein (PrPC) undergoes a self-propagating conformational change; the resulting
infectious conformer is designated PrPSc. Frequently, PrPSc is protease-resistant but protease-sensitive (s) prions have been
isolated in humans and other animals. We report here that protease-sensitive, synthetic prions were generated in vitro
during polymerization of recombinant (rec) PrP into amyloid fibers. In 22 independent experiments, recPrP amyloid
preparations, but not recPrP monomers or oligomers, transmitted disease to transgenic mice (n= 164), denoted Tg9949
mice, that overexpress N-terminally truncated PrP. Tg9949 control mice (n= 174) did not spontaneously generate prions
although they were prone to late-onset spontaneous neurological dysfunction. When synthetic prion isolates from infected
Tg9949 mice were serially transmitted in the same line of mice, they exhibited sPrPSc and caused neurodegeneration.
Interestingly, these protease-sensitive prions did not shorten the life span of Tg9949 mice despite causing extensive
neurodegeneration. We inoculated three synthetic prion isolates into Tg4053 mice that overexpress full-length PrP; Tg4053
mice are not prone to developing spontaneous neurological dysfunction. The synthetic prion isolates caused disease in
600–750 days in Tg4053 mice, which exhibited sPrPSc. These novel synthetic prions demonstrate that conformational
changes in wild-type PrP can produce mouse prions composed exclusively of sPrPSc.
Citation: Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, et al. (2010) Protease-Sensitive Synthetic Prions. PLoS Pathog 6(1): e1000736. doi:10.1371/
journal.ppat.1000736
Editor: Neil Mabbott, University of Edinburgh, United Kingdom
Received November 24, 2008; Accepted December 21, 2009; Published January 22, 2010
Copyright:  2010 Colby et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a gift from the G. Harold and Leila Y. Mathers Foundation and grants from the National Institutes of Health (NS064173,
AG02132, AG10770, and AG021601). D.W.C. was also supported by a postdoctoral fellowship from the Jane Coffin Childs Memorial Fund for Medical Research. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stanley@ind.ucsf.edu
¤a Current address: British Veterinary Association, London, United Kingdom
¤b Current address: Medical Biotechnology Center, University of Maryland Biotechnology Institute, Baltimore, Maryland, United States of America
¤c Current address: Neurobiology Sector, Scuola Internazionale di Studi Avanzati, Trieste, Italy
Introduction
Prions are infectious proteins that cause heritable, sporadic, and
transmissible disease in humans and other mammals [1]. The
molecular basis of prion disease is a conformational change in the
normal, cellular prion protein, denoted PrPC, to a disease-causing
form, denoted PrPSc [2,3]. This conformational change has often
been detected by measuring the extent to which PrP resists digestion
by proteases, such as proteinase K (PK), because most naturally
occurring prion strains are partially resistant to digestion [4,5,6,7].
However, a substantial portion of some prion strains is comprised of
protease-sensitive (s) PrPSc; for example, over 90% of PrPSc in the
brains of some sporadic Creutzfeldt-Jakob disease (sCJD) cases is
sensitive to PK digestion [8]. Importantly, cases of fatal neurological
disease have been reported with neuropathology typical of sCJD but
harboring no protease-resistant (r) PrPSc [9,10], and the
PrP(H187R) mutation gives rise to neurological disease with an
abnormal PrP conformer that is sensitive to protease digestion [11].
Atypical strains causing scrapie, a prion disease in sheep, have also
been reported with a high proportion of sPrPSc [12,13,14].
Transgenic (Tg) mice expressing mouse (Mo) PrP with the
P101L mutation corresponding to the human PRL mutation
causing Gerstmann-Stra¨ussler-Scheinker (GSS) disease also harbor
protease-sensitive prions. Tg(PrP,P101L) mice expressing high
levels of mutant PrP spontaneously develop prion disease and
generate a mutant form of PrPSc that is resistant only to mild PK
digestion [15,16,17]. Tg(PrP,P101L)196 mice expressing low levels
of mutant PrP were inoculated with brain extracts from ill Tg mice
overexpressing mutant PrP or a synthetic, 55-residue PrP(P101L)
peptide refolded into a b-rich conformation [18,19]. In the
inoculated Tg196 mice, both the brain extracts and the synthetic
peptide hastened the development of neurodegenration
[15,16,20]. Interestingly, prions with the P101L mutation were
not transmissible to mice expressing the wild-type (wt) PrP
sequence; whether this was due to the protease sensitivity of the
prions or the presence of the P101L mutation was not clear.
Inoculation of seeded and unseeded preparations of re-
cMoPrP(89–230) amyloid fibers into Tg9949 mice, which express
a similar, N-terminally truncated PrP at 16–326 the levels of PrP
in Syrian hamster brain [21], generated prions [22]. The brains of
mice that had been inoculated with the seeded PrP amyloids
produced a synthetic prion strain denoted MoSP1, which
exhibited protease resistance and shortened incubation periods
upon serial passage to both wt and Tg lines of mice [22,23,24].
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The extent to which the brains of mice that had been inoculated
with unseeded fibers harbored protease-resistant PrP was unclear
[22]. We hypothesized that Tg9949 mice inoculated with the
unseeded amyloid fibers, as described in our initial report [22], may
contain protease-sensitive prions since their brains exhibited all the
neuropathological features of prion disease. At that time, the most
reliable method of detecting sPrPSc was the conformation-
dependent immunoassay (CDI) [7,25], which consists of selective
precipitation of PrPSc by phosphotungstate (PTA) followed by
immunodetection. However, the CDI proved unreliable in
detecting sPrPSc due to the high levels of the transgene product
N-terminally truncated PrPC. For this reason, we sought an
alternative method for detecting sPrPSc; we called this new
procedure the amyloid seeding assay (ASA). The ASA employs
PTA precipitation, similar to the CDI, but detects prions based on
their propensity to hasten the formation of PrP amyloids. We found
that prions could be detected using the ASA in brain samples from
Tg9949 mice inoculated with the unseeded fibers [26].
Recently, several new strains of protease-resistant synthetic
prions have been created from amyloid generated under a variety
of conditions and inoculated into mice that overexpress full-length
PrP [27]. These findings expand the original report of synthetic
prions [22] to a second line of transgenic mice and confirm the
ability to create protease-resistant synthetic prions.
To extend our discovery that truncated wt mammalian prions
could be produced synthetically [22,27], we performed a large
series of experiments with various recMoPrP amyloid fibers in
Tg9949 mice. We sought conditions to produce synthetic prions
with abbreviated incubation times. While we investigated
numerous variations in the preparation of recMoPrP amyloids,
none resulted in a shortening of the incubation times. However,
most of the amyloid preparations caused prion disease in Tg9949
mice as demonstrated by neuropathological changes and the
presence of sPrPSc. These protease-sensitive prions transmitted
disease to two different Tg lines of mice. Unexpectedly, control,
uninoculated and mock-inoculated Tg9949 mice were prone to
late-onset neurological dysfunction that was indistinguishable
clinically from Tg mice inoculated with protease-sensitive prions.
But the ill, control Tg9949 mice did not develop neurodegener-
ation, form sPrPSc or transmit prion disease.
The studies reported here not only demonstrate the validity of
the experimental systems reported earlier but they also extend our
understanding of synthetic prions. Moreover, our findings establish
that wt sPrPSc alone, in the absence of detectable rPrPSc, is
sufficient to cause neurodegeneration.
Results
Control Tg9949 mice develop spontaneous neurological
dysfunction
To determine if Tg9949 mice generate prions spontaneously, 96
uninoculated Tg9949 mice and 78 Tg9949 mice inoculated with
bovine serum albumin (BSA) were monitored twice weekly for signs
of neurological dysfunction.We found that a cumulative incidence of
85% of these control Tg mice developed late-onset ataxia at
approximately 600 d (Fig. 1A and Table S1). The most common
clinical observations of aged Tg9949 mice were ataxia, circling, and
a dull coat. Mice inoculated with BSA were no more likely than
uninoculated mice to develop neurological dysfunction (Fig. 1A and
Table S1). We compared the probability of these Tg9949 mice
developing ataxia in old age to the probability that other Tg and wt
mice develop ataxia. We found that Tg9949 mice are significantly
more likely to develop ataxia than wt FVB mice (n=12; p=0.03)
and Tg mice that express full-length PrP at 4–8 times wt levels
(Tg4053 mice, n=62; p,0.001) [17,27,28]. Older Tg4053 and FVB
mice had comparable rates (p.0.30) of neurological dysfunction.
We used four different methods to determine if Tg9949 mice
suffering from neurological dysfunction had spontaneously gener-
ated prions: bioassay, neuropathology, Western blotting for
rPrPSc, and ASA for sPrPSc [26]. For bioassays, brains from three
Tg9949 mice exhibiting neurological dysfunction were homoge-
nized and inoculated intracerebrally (ic) into weanling Tg9949 and
Tg4053 mice. Inoculation of these brain homogenates neither
hastened the onset of neurological dysfunction in Tg9949 mice nor
resulted in neurological dysfunction in Tg4053 mice (Fig. 1B). In
contrast, inoculation of Rocky Mountain Laboratory (RML)
prions into Tg9949 and Tg4053 mice mice resulted in disease in
161 d and 50 d, respectively [21].
For neuropathological analyses, we examined more than 20 brain
samples from Tg9949 mice exhibiting neurological dysfunction (from
both the uninoculated and BSA-inoculated groups; Fig. 1A).
Typically, neuropathologic features of prion disease include the
formation of vacuoles, proliferation of astrocytes, and deposition of
PrP aggregates [29]. We found no evidence of prion disease pathology
in any of the brains taken from aged Tg9949 mice (a representative
specimen is shown in Fig. 1C). Occasional vacuoles and mild
astrocytic gliosis of the cerebellar white matter were observed, but
these findings were consistent with aging (for comparison with aged,
healthy Tg9949, wt, and Tg4053 mice, see Fig. S1). Neuropatho-
logical analysis did not indicate the cause of neurological dysfunction
in older uninoculated or BSA-inoculated Tg9949 mice.
To determine whether Tg9949 mice suffering from neurological
dysfunction harbored protease-resistant PrP, we performed
Western immunoblotting of brain samples. In over 100 mouse
brains from uninoculated and BSA-inoculated Tg9949 mice, we
found no PK-resistant PrP signal. Six independent samples are
shown in Fig. 1D.
Next, we subjected the brain homogenates of Tg9949 mice to the
ASA (Fig. 1E) [26]. This assay is based on the observation that
prions, partially purified from brain homogenates by PTA precip-
itation [7], accelerate the conversion of recPrP into a conformation
that favors amyloid assembly [26]. We incubated PTA-precipitated
brain homogenates with recMoPrP(89–230) for 6 h and monitored
amyloid formation by measuring the fluorescence emission of
Author Summary
Prions are infectious proteins that cause heritable,
sporadic, and transmissible diseases in humans and other
mammals. These infectious proteins arise when the normal
form of the prion protein (PrP) adopts a self-perpetuating
conformation. This disease-causing PrP form is frequently
distinguished from normal PrP by its resistance to digestion
by proteases although considerable evidence shows that
protease-sensitive prions occur naturally in humans and
sheep. Here we describe the generation of novel protease-
sensitive synthetic prions. After producing recombinant PrP
of the wild-type mouse sequence in Escherichia coli, we
polymerized the protein into an amyloid fiber conforma-
tion. Mice inoculated with these amyloid fibers developed
extensive neurodegeneration characteristic of prion dis-
ease, but did not generate protease-resistant PrP. Prions
from sick animals were transmitted to healthy animals,
which likewise developed neurodegeneration but not
protease-resistant prions. These novel synthetic prions
demonstrate that truncated wild-type PrP can undergo a
conformational change that becomes infectious yet the
protein remains protease sensitive.
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Thioflavin T (ThT) [30]. As depicted, samples from RML prion-
inoculated animals were active in the ASA whereas samples from
BSA-inoculated Tg9949 mice were not (Fig. 1E, top). Because
amyloid seeding is a kinetic process, we wanted to be certain that
none of the samples had an intermediate effect on amyloid formation
that did not register on the time scale of the initial measurement (6 h).
We measured the mean lag phase for amyloid formation for all of the
samples, and found that all uninoculated and BSA-inoculated
Tg9949 samples showed lag times similar to uninoculated FVB
control brains (Fig. 1E), indicating that aged Tg9949 mice do not
spontaneously form protease-sensitive prions. In contrast, the brains
of RML prion-inoculated mice were able to reduce the lag phase for
amyloid formation (Fig. 1E, bottom).
Inoculation of Tg9949 mice with monomeric, oligomeric
and amyloid PrP
We inoculated Tg9949 mice with recPrP(89–230) in a-helical
(monomeric), b-rich oligomeric and amyloid forms. In addition to
Figure 1. Tg9949 mice are prone to neurological dysfunction but do not spontaneously generate prions. (A) Wild-type (FVB), Tg4053,
and Tg9949 mice were monitored for signs of neurological dysfunction for .900 days. Both uninoculated and BSA-inoculated Tg9949 mice were
more likely than wt mice (p = 0.03) and Tg4053 mice (p,0.001) to develop neurological dysfunction. However, prions could not be detected in the
brains of neurologically impaired Tg9949 mice, as determined by bioassay in Tg9949 and Tg4053 mice (B), by histopathological staining (C), by
Western immunoblotting (D), and by the amyloid seeding assay (E). (C) Brain sections of neurologically impaired Tg9949 mice were stained with H&E
to visualize vacuoles (left), a-GFAP to visualized astrocytic gliosis (middle), and a-PrP to visualize PrPSc deposits (right). Scale bars represent 100 mm.
Mol, molecular cell layer; GC, granular cell layer; WM, white matter. Additional neuropathological analyses of control brains are shown in Fig. S1. (D)
Western immunoblots of undigested and PK-digested brain samples from six aged Tg9949 mice show no rPrPSc. Homogenate from a Tg9949 mouse
inoculated with RML prions is shown as a positive control. Lane assignments are as indicated in panel E. (E) Brain samples from six aged Tg9949 mice
do not seed the formation of recPrP amyloid, as judged by an increase in Thioflavin T fluorescence (top) and by a decrease in the lag phase for
amyloid formation (bottom). An uninoculated FVB mouse brain is included as a negative control. Negative controls in (A) are pooled results, including
some previously published data [27].
doi:10.1371/journal.ppat.1000736.g001
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the two amyloid inoculations previously reported [22] (Amyloids 1
and 2; Table S2), we made 24 independent amyloid preparations
by systematically varying the conditions used for amyloid
formation including: (1) the initial conformation of recMoPrP,
(2) the composition and concentration of denaturant, (3) the
number of times the seeding procedure was repeated, (4) use of
multiple freeze-thaw cycles, and (5) the method used to purify the
fibers prior to inoculation (Amyloids 3–4, Amyloids 14–35, Table
S2). We inoculated monomeric recMoPrP(89–230), oligomeric
recMoPrP(89–230), and each of the 24 new amyloid preparations
into groups of at least eight Tg9949 mice. All inoculated Tg9949
mice developed neurological dysfunction between 500 and 650
days (Table S3). Tg9949 mice inoculated with protease-sensitive
synthetic prions had clinical presentations that were indistinguish-
able from control mice as they aged, specifically, ataxia, circling,
and a dull coat.
To determine if the brains of inoculated Tg9949 mice harbored
prions, we analyzed brain samples by Western immunoblotting
and the ASA (Fig. 2A–C and Table S3). In the brains of mice
that had been inoculated with Amyloids 2, 3, or 4, no PK-resistant
PrP was detected using any of three different antibodies (P, D18,
and R2, which bind to the N-terminal, middle, and C-terminal
regions of PrP(89–230), respectively; immunoblot probed with P is
shown in Fig. 2A). Likewise, no PK-resistant PrP was detected in
the brains of mice inoculated with Amyloids 14–35 by immuno-
blotting with the antibody D18 (Table S3). However, brain
samples from mice that had been inoculated with 21 of the 24 new
amyloid preparations showed substantial activity in the ASA,
indicating the presence of prions; for the remaining three
amyloids, no prions were detected (Figs. 2B, S2, and Table
S3). We found that the brains of Tg9949 mice inoculated with PrP
in an a-helical, monomeric conformation [31] and those
inoculated with PrP in a b-rich oligomeric form [32] did not
contain PrP in a conformation that was active in the ASA (Fig. 2C,
top). We also measured mean lag phases in the ASA to be certain
that no intermediate seeding effect had occurred (Fig. 2C,
bottom). Examination of the brains of ill, amyloid-inoculated
animals by histopathology revealed the hallmarks of prion disease,
including extensive vacuole formation and PrP deposits, either
lining the vacuoles or as punctate aggregates near the vacuoles
(Fig. 2D and Table S3). Tg9949 mice inoculated with the a-
helical or b-oligomeric recPrP had normal brains histologically
with no evidence of prion disease. Based on the ASA activity and
neuropathology, we conclude that 21 of the 24 new amyloid
preparations resulted in the formation of protease-sensitive prions,
which were transmissible to Tg9949 mice. We chose three brain
isolates for further study and designated the resulting prion strains
MoSP2, MoSP3, and MoSP4, respectively.
Because this was the first time that the ASA has been applied to
a large number of unknown samples, we analyzed the correlation
of this method to neuropathological analysis. Forty-six samples
were analyzed for the presence of prions both by neuropathology
and the ASA; of these, 34 were positive by both methods, 11 were
negative in both, and 1 was positive in the ASA but negative by
neuropathology (Table S4). Thus, results by the ASA correlated
with neuropathologic assessment for 98% of samples (p,0.001).
Serial transmission of protease-sensitive synthetic prions
in Tg9949 mice
Brain homogenates from ill Tg9949 mice containing MoSP2,
MoSP3, and MoSP4 prions were inoculated ic into Tg9949 mice.
Brain homogenates from aged Tg9949 mice with neurological
dysfunction were used as controls. Serial transmission (or second
transmission, 2T) of all three protease-sensitive synthetic prion
strains in Tg9949 mice resulted in neurological dysfunction within
a timeframe comparable to uninoculated, control mice (Table
S5). A third transmission (3T) of MoSP2 into Tg9949 mice gave
similar results (Table S5).
Figure 2. Inoculation of Tg9949 mice with PrP amyloid, but not
other PrP conformations, results in the generation of prions.
Tg9949 mice were inoculated with recPrP folded in various conforma-
tions (a-helical, b-rich, and amyloid) and allowed to live out their normal
life span (Table S2 and S3). Tg9949 mice inoculated with BSA or
MoSP1 [22] are shown as controls. The first transmission (1T) of MoSP2,
MoSP3, and MoSP4 refers to inoculation of Tg9949 mice with amyloid 2,
amyloid 3, and amyloid 4 preparations, respectively. Brain samples from
Tg9949 mice containing MoSP2, MoSP3, or MoSP4 did not harbor
protease-resistant PrP (A) but showed activity in the ASA (B; kinetic
data shown in Fig. S2; note that the sample amount for ASA is 1/1000
of the amount used in Western blots). Brain samples from mice
inoculated with non-amyloid PrP conformations did not show activity in
the ASA (C). Activity in the ASA was detected by an increase in ThT
fluorescence (B and top of panel C) and by a decrease in the mean
lag phase for PrP amyloid formation (bottom of panel C). (D) Brain
sections of Tg9949 mice containing MoSP2, MoSP3, or MoSP4 showed
neuropathology consistent with prion disease, including extensive
vacuolation (H&E stain, left column) and PrP deposition (anti-PrP stain,
right column). Each scale bar represents 100 mm and applies to the
micrographs in the same column.
doi:10.1371/journal.ppat.1000736.g002
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We wished to determine whether the protease sensitivity and
ASA activity of MoSP2, MoSP3, and MoSP4 were maintained
upon serial passage in Tg9949 mice. Western blots of brain
samples from Tg9949 mice serially infected with MoSP2, MoSP3,
and MoSP4 were probed with anti-PrP antibody P and revealed
no protease-resistant PrP fragments (Fig. 3A). MoSP1 was used as
a PK-resistant positive control. Employing lower concentrations of
PK (1, 3, and 10 mg/ml) revealed no difference between Tg9949
mice inoculated with MoSP2 and uninoculated Tg9949 controls
(Fig. S3). We next subjected brain homogenates of mice that had
received serial transmission of MoSP2, MoSP3, and MoSP4 to the
ASA. PTA-purified brain homogenates were incubated with
recMoPrP(89–230) for 6 h, and amyloid formation was monitored
by ThT fluorescence. MoSP2, MoSP3, and MoSP4 serially
passaged in Tg9949 mice exhibited consistent activity in the
ASA (Fig. 3B). In contrast, brain homogenates from control mice
inoculated with a mock inoculum (Tg9949 brain homogenate) did
not seed amyloid formation.
Next, we analyzed brain sections of Tg9949 mice serially
infected with MoSP2, MoSP3, and MoSP4. Serial passage of each
protease-sensitive synthetic prion strain resulted in substantial
vacuolation and formation of PrP deposits (Fig. 3C). Vacuolation
scores, or the area of a region occupied by vacuoles, were
tabulated for various brain regions from the initial transmission,
second transmission, and third transmission of MoSP2 in Tg9949
mice (Fig. S4). Vacuolation in Tg9949 mice infected with MoSP2
by serial passage was similar to that in Tg9949 mice originally
inoculated with amyloid fibers, indicating that the strain
characteristics of MoSP2 were conserved upon passage. Finally,
brain sections of mice inoculated with MoSP2 were subjected to
histoblot analysis with and without PK digestion (Fig. S5), which
confirmed that PrP deposits in the brains of mice inoculated with
MoSP2 are protease-sensitive.
Serial transmission of protease-sensitive synthetic prions
to mice expressing full-length PrP
Tg9949 brain homogenates containing MoSP2 were inoculated
ic into Tg4053 mice, which overexpress full-length MoPrP-A.
Additionally, two Tg9949 brain homogenates inoculated with
Amyloid Prep 19 (Table S3) were passaged to Tg4053 mice. In
contrast to Tg9949 mice, Tg4053 mice are not prone to
developing late-onset ataxia (Fig. 1A). Transmission of MoSP2
and the other protease-sensitive synthetic prion isolates to Tg4053
mice resulted in prion disease with incubation periods of 600–
750 d (Fig. 4A). Tg4053 mice inoculated with protease-sensitive
synthetic prion isolates were significantly more likely to develop
neurological dysfunction than Tg4053 mice inoculated with brain
homogenate from uninoculated aged Tg9949 mice (p,0.001).
Brain samples of Tg4053 mice inoculated with protease-sensitive
synthetic prion isolates showed no rPrPSc in Western blots (MoSP2
shown in Fig. 4B), but substantial activity in the ASA (MoSP2
shown in Fig. 4C). In contrast, Tg4053 mice inoculated with
control Tg9949 brain homogenates had neither rPrPSc nor sPrPSc.
To detect trace quantities of rPrPSc in Tg4053 mice inoculated
with MoSP2, we subjected 1 ml of 5% brain homogenate to PK
digestion (20 mg/ml), followed by PTA precipitation (Fig. S6).
The PTA pellet was resuspended in 100 ml of 10% SDS and
boiled. Thirty microliters of the resulting product was then
analyzed by Western immunoblotting, approximately 10-fold
more material than used elsewhere in this work for Western blots
and 1000-fold more material than used for the ASA. Even under
these conditions, no rPrPSc could be detected. Neuropathology
consistent with prion disease was observed in brain sections from
MoSP2-inoculated Tg4053 mice (Fig. 4D). Punctate PrP deposits
and vacuolation were widespread, but most severe in the CA1
region of the hippocampus and in the cerebellum (Fig. S4). From
these data, we conclude that protease-sensitive synthetic prions in
the brains of Tg9949 mice were transmitted to Tg4053 mice, and
the resulting prions were composed of sPrPSc and produced
neuropathologic changes typical of prion disease. Notably, MoSP2
produced no clinical or pathologic evidence of prion disease in wt
FVB mice (Table S6).
Discussion
Encouraged by the production of prion infectivity by polymer-
izing recMoPrP(89–230) into amyloid fibers [22,23], we undertook
a study aimed at identifying conditions that would shorten
Figure 3. Protease-sensitive synthetic prions are serially transmissible in Tg9949 mice. MoSP2-1T, MoSP3-1T and MoSP4-1T were serially
passaged to new groups of Tg9949 mice for a second transmission (2T) by intracerebral inoculation of brain homogenate containing each isolate.
MoSP2-2T was serially passaged an additional time for a third transmission (3T). In each case, the animals lived a normal life span (Table S4). The
brains of Tg9949 mice containing MoSP2-2T, MoSP3-2T, or MoSP4-2T showed no protease-resistant PrP by Western blotting (A), but activity in the
ASA (B) and neuropathology consistent with prion disease (C). Brain samples from mice inoculated either with MoSP1 [22] or with homogenates of
uninfected Tg9949 mice are shown as controls. (C) Cerebellar sections were stained with H&E (top row) and a-PrP (bottom row). m, molecular layer;
gc, granule cell layer. Each scale bar represents 100 mm and applies to the panels in the same row.
doi:10.1371/journal.ppat.1000736.g003
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incubation times for synthetic prions in Tg mice. We explored an
array of variables, including the composition and concentration of
denaturant, the number of seeding rounds, and the number of
freeze-thaw cycles, none of which modified experimental out-
comes. Twenty-five preparations of recMoPrP(89–230) polymer-
ized into amyloid were inoculated into 204 Tg9949 mice. Eighty
percent (or 164) of the Tg9949 mice were found to have sPrPSc
and neuropathology typical of experimental prion disease. Three
of the amyloid preparations failed to produce measurable sPrPSc
and neuropathology while six other preparations showed incom-
plete transmissions (Table S3). Three of the 22 infectious,
recMoPrP amyloid preparations were studied in detail; these were
designated MoSP2, MoPSP3 and MoSP4. Each of these synthetic
prion isolates transmitted disease upon serial passage in Tg9949
mice (Fig. 3). In addition, MoSP2 and two other protease-
sensitive synthetic prion isolates transmitted disease to Tg4053
mice overexpressing MoPrP (Fig. 4).
Our creation of these novel protease-sensitive prions challenges
the accepted definition of what constitutes a prion. Mammalian
prions have been most closely associated with PrP that resists
protease digestion [4,5,6,7]. Additionally, mammalian prions
typically cause disease that shortens the lifespan of the animal.
While the novel synthetic prions reported here do not have either
of these characteristics, they share four traits common to all
mammalian prions: (1) they possess an alternatively folded isoform
of PrP (Fig. 2B); (2) they cause neurologic dysfunction in animals
(Fig. 4A); (3) they cause profound neuropathologic changes
(Fig. 2D and 4D); and (4) they are transmissible (Figs. 3 and 4).
We suggest that these four traits define mammalian prions.
Many prions observed in nature appear to be composed of
mixtures of rPrPSc and sPrPSc [7,8,12,13,14,25], though the
relationship between the two is unclear. The creation of synthetic
prions composed solely of sPrPSc offers new insight into this
relationship and the role of sPrPSc in disease. Our results
demonstrate that sPrPSc is transmissible and causes neurodegen-
eration in the absence of rPrPSc. Our findings also suggest that
sPrPSc does not arise as an off-pathway product during the
replication of rPrPSc. Examples of natural prion diseases that
feature sPrPSc predominantly are rarely reported [9,10]. In the
work reported here, it was necessary to use genetically modified
lines of mice to make this unusual prion phenotype more readily
accessible. Notably, inoculation of wt FVB mice with the amyloid
fibers used in these studies did not result in prion disease (Table
S7).
It is intriguing that MoSP2 remained protease-sensitive even
after repeated serial passage. The protease-sensitive prion fraction
isolated from Syrian hamsters infected with 263K prions was
shown to give rise to rPrPSc in the protein misfolding cyclic
amplification assay [33]. Our findings indicate that infection with
sPrPSc does not necessarily lead to rPrPSc generation.
Because some lines of Tg mice overexpressing wt PrP develop
spontaneous neurological dysfunction [34], we observed 96
uninoculated, control Tg9949 mice and ic inoculated 78 control
Tg9949 mice with BSA in PBS. Unexpectedly, most of these
control Tg9949 mice developed late-onset, spontaneous neuro-
logical dysfunction. All the ill, control Tg9949 mice showed no
neuropathological changes typical of prion disease. Additionally,
no sPrPSc or rPrPSc was detected in the brains of these control
Tg9949 mice. These studies established the validity and limitations
of transmitting prions to Tg9949 mice.
In our initial report of synthetic prions, we described the onset
of neurological dysfunction in Tg9949 mice between 380 and 660
days after inoculation [22]. Three sets of Tg9949 mice were used
as controls. In the first set, 10 of 12 healthy, uninoculated Tg mice
were terminated at 574 days of age; the other two Tg9949 mice
developed signs of neurological dysfunction at 564 and 576 days of
age but had neither rPrPSc nor neuropathology typical of prion
disease. In the second set of control mice, eight Tg9949 mice were
inoculated with Syrian hamster Sc237 prions and were healthy at
525 days of age when they were sacrificed. Third, seven Tg9949
mice were inoculated with PBS and remained healthy at 672 days
of age when they were sacrificed. In light of the current work, the
first and second control groups were terminated too early to
observe neurological dysfunction and the third group appears to
be an outlier. Our discovery that Tg9949 mice develop late-onset
neurological dysfunction does not undermine the key finding of the
earlier work [22], which demonstrated that prions could be
generated de novo from recombinant protein, but it does raise the
possibility that the incubation period for the initial transmission
may have been longer than reported. Incubation periods for some
prion strains in Tg9949 mice cannot be determined when they
approach or exceed the age of onset of spontaneous neurological
dysfunction in these mice.
Despite the observation that uninoculated, control Tg9949 mice
were prone to ataxia in old age, we found no evidence of prions in
these mice by biochemical means, by histopathology, or by
Figure 4. Protease-sensitive synthetic prions are serially
transmissible to Tg4053 mice. Tg4053 mice intracerebrally inocu-
lated with MoSP2-1T (red), MoSP19A (blue) or MoSP19B (purple)
developed signs of prion disease between 600–750 d (A). MoSP19A and
MoSP19B are two Tg9949 brain isolates inoculated with Amyloid Prep
19 (origin in Table S3). Tg4053 mice inoculated with protease-sensitive
synthetic prions were significantly more likely to develop neurological
dysfunction than mice inoculated with uninfected Tg9949 brain
homogenate (black, p,0.001). PrP in the brains of these mice was
sensitive to PK digestion (B) and active in the ASA (C). MoSP1 was used
as a control. The brains of ill, MoSP2-inoculated Tg4053 mice showed
neuropathology consistent with prion disease (D), including vacuola-
tion (top panel), astrocytic gliosis (middle panel), and punctate PrP
deposits (bottom panel). Scale bars represent 100 mm.
doi:10.1371/journal.ppat.1000736.g004
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attempted serial transmission of their brain homogenates (Fig. 1).
Neuropathological analysis of the brains of these mice excluded
that neurologic dysfunction was caused by the spontaneous
generation of prions. It is noteworthy that neurological deficits
in Tg mice overexpressing PrP are not uncommon and are distinct
from those caused by prion infection. Tg mice overexpressing wt
MoPrP-B, Syrian hamster PrP, or ovine PrP develop disease
featuring hindlimb paralysis, tremors, and ataxia, with mean ages
of onset at ,550 days [34]. Deletion of specific N-terminal
segments of PrP results in fatal ataxia accompanied by
degeneration of the cerebellum at 90–275 days of age [35].
Deletions of helical regions near the C-terminus result in CNS
illnesses similar to neuronal storage diseases [36]. Like Tg9949
mice, none of these neurologically compromised mice spontane-
ously generated prions.
Evidence of prion disease was observed in 22 of 25 amyloid
inoculations in Tg9949 mice, but was not observed from any of 7
control inoculations, including PBS, BSA, a-helical recPrP, b-
oligomeric recPrP, and 3 uninfected Tg9949 brain homogenates.
These results exclude the possibility that the observed neuropa-
thology resulted from contamination of the inocula.
It is possible that a small titer of rPrPSc that eluded detection is
responsible for the disease observed in these studies. Given the
extensive neurodegeneration observed in the brains of infected Tg9949
mice (Fig. S4), this possibility seems unlikely. In fact, the vacuolation
profile generated by inoculating the protease-resistant MoSP1 strain
into Tg9949 mice was much less severe than that observed for MoSP2
prions, which lack protease-resistance [22]. Furthermore, despite its
tendency to accumulate, no rPrPSc could be detected even upon serial
passage (Fig. 3). Nonetheless, it is conceivable that some rPrPSc may be
detectable under conditions not yet explored, for example, using
alternate proteases. This would not alter our conclusions, however, that
such protease-sensitive prions would be overlooked using the standard
conditions used to detect prions.
Whereas protease-sensitive prions composed of mutant
PrPSc(P101L) in Tg mice have been studied extensively
[15,16,17], wt sPrPSc has been less well investigated. While rPrPSc
is clearly transmissible, it is unknown what role, if any, rPrPSc plays
in the pathogenesis of prion disease. From the studies reported
here as well as other investigations, sPrPSc is clearly pathogenic.
The pathogenicity of sPrPSc calls into question the adequacy of
some terms used to describe different isoforms of PrP, such as
PrPres and PrPsen [37]. PrPres is often equated with PrPSc, and
PrPsen with PrPC. From the work presented here, we contend that
PrPSc can be both protease-resistant and protease-sensitive,
rendering terms that describe only the protein’s response to
limited protease digestion as ambiguous. Therefore, the use of
terms describing both infectivity and resistance to protease
digestion (i.e., sPrPSc, rPrPSc, and PrPC) is necessary in order to
avoid confusion.
While inoculation ic of recMoPrP(89–230) amyloid did not
shorten the lives of Tg9949 mice (Table S2), the amyloid
preparations provoked severe neurodegeneration (Fig. 2). Serial
transmission of protease-sensitive prions MoSP2, MoSP3, and
MoSP4 in Tg9949 mice did not alter the incubation periods
(Table S5), suggesting that these prion isolates encipher long
incubation times.
Because the formation of rPrPSc has been used as an operational
assay for the identification of prions, protease resistance has been
often viewed as an intrinsic and obligatory feature of prions [38].
The results reported here extend our more recent findings that
challenge the notion that protease resistance is an obligatory
feature of PrPSc that is required for the transmission of prions
[4,16].
The production of synthetic prions, which are sensitive to
proteolysis but cause transmissible disease, is an important step
toward understanding the role of protease-sensitive forms of PrPSc
in the pathogenesis of prion disease. Recent reports suggest that
prions with low levels of rPrPSc occur naturally in sheep [14] and
humans [9]. Our results show the importance of using alternate
methods for detecting PrPSc, rather than employing only the
presence of PK-resistant PrP. Exclusive reliance on the detection
of rPrPSc as a surrogate marker for prion infectivity may overlook
the contribution of sPrPSc to prion infectivity and the pathogenesis
of prion disease [39].
Materials and Methods
Ethics statement
All animal procedures were performed under protocols
approved by the Institutional Animal Care and Use Committee
at the University of California San Francisco.
Recombinant PrP
RecMoPrP(89–230) was made as previously described [22,40].
For inoculation into Tg9949 mice, recMoPrP(89–230) was
refolded into an a-helical conformation at 0.5 mg/ml [31], a b-
rich oligomer at 1.0 mg/ml [32], or into amyloid fibers at 1.0 mg/
ml [22]. For recPrP used in the ASA, lyophilized protein was
dissolved in 6 M Gdn at 5 mg/ml, aliquotted, and stored at
280uC.
Transgenic mice
Tg9949 mice [also referred to as Tg(MoPrP,D23–88)9949/Prnp0/0
mice] were bred in-house and express MoPrP(89–231) on a knockout
background at 16–326 compared to PrP in Syrian hamsters [21].
Tg4053 mice [also referred to as Tg(MoPrP-A)4053 mice] [28] were
bred in-house and express full-length PrP at 4–86 the levels in wt,
FVB mice [17]. FVB mice were obtained from Charles River
Laboratories (Wilmington, MA).
Preparation of brain homogenates
To prepare 10% (w/v) brain homogenates, 9 volumes of ice-
cold PBS were added to brain tissue in a 50-ml tube. Brain tissue
was homogenized on ice, using either needle extrusion through
progressively smaller needles, or, for samples used in the ASA, by
bead beating (FastPrep FP120, Qbiogene). The sample was
centrifuged at 5006 g for 5 min at room temperature (RT) to
clarify samples. The supernatant was collected, the pellet
discarded; aliquots were keep frozen at 280uC until use.
Inoculation
RecPrP was inoculated following dialysis against PBS to remove
toxic buffer components; alternatively, the fibers were washed 36
in PBS to remove toxic buffer components. Each time, fibrils were
spun down at maximum speed in a tabletop centrifuge and
resuspended in PBS as indicated in Table S2. For serial passage
experiments, 10% brain homogenates from Tg9949 mice were
diluted 1:10 in 5% BSA in PBS. Approximately 30 ml of recPrP,
PBS (with or without 5 mg/ml BSA), or diluted brain homogenate
were inoculated intracerebrally into mice of either sex, aged 7 to
10 weeks. Inoculation was carried out with a 27-gauge, disposable
hypodermic needle inserted into the right parietal lobe.
Mice were examined twice weekly for neurological dysfunction.
Animals were assessed using standard diagnostic criteria for prion
disease [41,42]. If neurological dysfunction was evident, mice were
sacrificed and their brains were removed for biochemical and
histological analysis.
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PK digestion and Western blots
Brain homogenates were adjusted to 1 mg/ml total protein;
20 mg/ml PK (Boehringer Mannheim) was added for a final
volume of 0.5 ml. Following a 1-h incubation at 37uC, digestion
was stopped by addition of phenylmethylsulfonyl fluoride (PMSF;
2 mM final concentration). Digestion products were precipitated
by centrifugation at 100,0006 g for 1 h, resuspended in SDS
loading buffer, and run on 12% polyacrylamide gels. Western
blotting was carried out as previously described [41] using anti-PrP
HuM-D18, P, or R2.
Amyloid seeding assay
The ASA was performed as described elsewhere [26], except
that PTA pellets were prepared on 1/5 scale (100 ml of 5% BH
was used as starting material, and all volumes scaled down
proportionally). Briefly, brain homogenates in Sarkosyl were
precipitated with PTA to purify prions. Two ml of PTA-purified
brain homogenates were diluted into 400 ml water, then tested as
seeds in amyloid formation reactions. A 96-well plate was
prepared with 180 ml/well of recPrP solution (50 mg/ml
recMoPrP(89–230), 0.4 M GdnHCl, 16 PBS, 10 mM ThT).
Twenty ml of diluted PTA-precipitated brain homogenate were
added to each well, with each sample tested with six replicates.
ThT fluorescence measurements were taken at 444/485 nm
excitation/emission spectra on an M2 Spectramax fluorescence
plate reader (Molecular Devices) after 6 h of continuous shaking
at 37uC. Each sample was measured in six independent
replicates.
Prion strain MoSP1
MoSP1 used as a PK-resistant control in these experiments was
passaged in either Tg9949 or Tg4053 mice [22].
Neuropathology
Brains were fixed immediately upon being harvested by
immersion in 10% buffered formalin. Following paraffin embed-
ding, 8-mm-thick sections were stained with H&E to visualize
vacuoles. Reactive astrocytic gliosis was visualized by peroxidase
immunohistochemistry with an antibody against glial fibrillary
acidic protein. The antibody R2 was used to visualize PrP deposits
[43]. Distributions of neuropathological lesions were estimated as
the percentage of tissue occupied by vacuoles. These estimates
were confirmed by a second, independent technician.
Statistical analysis
For survival analysis, STATA software (StataCorp, College
Station, TX) was used to calculate p-values based on cumulative
survival. Microsoft Excel (Microsoft Corp., Redmond, WA) was
used to calculate standard deviations and standard errors.
Supporting Information
Figure S1 Tg9949 mice with neurological dysfunction exhibit
the same neuropathology associated with aging of wild-type and
other transgenic mice. The cerebellum of a Tg9949 mouse
exhibiting neurological dysfunction (ND) is compared with age-
matched, healthy Tg9949 mice, wild-type FVB mice, and Tg4053
mice. Mild vacuolation (white holes observed in H&E-stained
panels, top row) and astrocytic gliosis (dark brown spots labeled
with anti-GFAP, bottom row) are observed in the white matter in
all mice examined. Scale bar represents 100 mm and applies to all
panels.
Found at: doi:10.1371/journal.ppat.1000736.s001 (0.31 MB PDF)
Figure S2 Sample kinetic data from the amyloid seeding assay.
PTA pellets were generated from the brains of Tg9949 mice
inoculated with BSA (blue diamonds), a-helical recPrP (blue
triangles), b-oligomeric recPrP (blue circles), or amyloid fibrils of
recPrP to generate MoSP2-1T (red triangles), MoSP3-1T (red
circles), and MoSP4-1T (red squares); these pellets were added
amyloid formation reactions in the presence of ThT. ThT
fluorescence, indicating the presence of amyloid, was measured
as a function of time. PTA pellets from MoSP2, MoSP3, and
MoSP4 efficiently seeded amyloid formation, whereas the other
PTA pellets did not. PTA pellets of uninoculated Tg9949 mice are
also shown (blue squares).
Found at: doi:10.1371/journal.ppat.1000736.s002 (0.03 MB PDF)
Figure S3 Protease-resistant PrP is not detected in the brains of
mice inoculated with MoSP2. Even at lower concentrations of PK,
no difference in protease-resistant PrP fractions can be discerned
between MoSP2-inoculated and uninoculated Tg9949 mice. Brain
homogenates at protein concentrations of 1 mg/ml were incubat-
ed with PK at the indicated concentrations for 1 h at 37uC. The
blot was probed with a-PrP antibody HuM-D18. Molecular
weight standards are indicated on the left in kDa.
Found at: doi:10.1371/journal.ppat.1000736.s003 (0.02 MB PDF)
Figure S4 Vacuolation scores, estimated as the percentage of an
area occupied by vacuoles, in different brain regions of Tg9949 (A)
and Tg4053 mice (B) inoculated with MoSP2. (A) In Tg9949 mice,
the first transmission (1T) and each subsequent serial transmission
(2T and 3T) of MoSP2 resulted in widespread vacuolation, with
comparable levels of vacuolation observed in each brain region.
Note that no vacuolation (0%) is observed in BSA-inoculated
Tg9949 mice. Asterisk indicates that age-related vacuolation was
excluded in this scoring. Vacuolation resulting from passage of
MoSP1 in Tg4053 mice (B) is shown for comparison. LC, limbic
cortex; FC, frontal cortex; DG, dentate gyrus; CA, cornu ammonis
of the hippocampus; LT, lateral thalamic nuclei; MT, medial
thalamic nuclei; Cd, caudate nucleus; Cm, cerebellar molecular
layer; Cg, cerebellar granule cell layer; Cw, cerebellar white
matter; Bs, brainstem.
Found at: doi:10.1371/journal.ppat.1000736.s004 (0.04 MB PDF)
Figure S5 Histoblots of cerebellar brain sections show that PrP
deposits in MoSP2-inoculated Tg9949 mice are protease sensitive.
Sections were prepared from Tg9949 mice inoculated with brain
homogenates of aged Tg9949 mice (control), MoSP1, or MoSP2.
Only brains inoculated with MoSP1 show protease-resistant PrP.
Histoblots from brains inoculated with MoSP2 are comparable to
control Tg9949 mice. Histoblots were probed with HuM-D18.
Found at: doi:10.1371/journal.ppat.1000736.s005 (0.03 MB PDF)
Figure S6 Western blots of 5% Tg4053 brain homogenates after
PK digestion and PTA precipitation reveal no rPrPSc. PK
digestion was performed at 20 mg/ml for 1 h at 37uC; PTA
precipitation was performed in 2% Sarkosyl with 1% PTA at
pH 7.4, for 1 h at 37uC. Brain homogenates from Tg4053 mice
inoculated with either uninfected (-control) or MoSP1-infected
Tg9949 brain homogenates are shown as controls. One ml of
brain homogenate was precipitated, 30% of which was run on the
gel, approximately 1000-fold as much homogenate as was used for
the ASA. The blot was probed with m-PrP antibody HuM-P.
Apparent molecular masses based on the migration of protein
standards are shown in kDa.
Found at: doi:10.1371/journal.ppat.1000736.s006 (0.02 MB PDF)
Table S1 Spontaneous neurological dysfunction in Tg9949
mice.
Found at: doi:10.1371/journal.ppat.1000736.s007 (0.04 MB PDF)
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Table S2 Conditions used for the formation of amyloid fibers.
Found at: doi:10.1371/journal.ppat.1000736.s008 (0.02 MB PDF)
Table S3 Initial transmission of synthetic prions by inoculation
of Tg9949 mice with amyloid fibers.
Found at: doi:10.1371/journal.ppat.1000736.s009 (0.02 MB PDF)
Table S4 Samples analyzed by ASA and neuropathology.
Found at: doi:10.1371/journal.ppat.1000736.s010 (0.03 MB PDF)
Table S5 Serial transmission of protease-sensitive synthetic
prions in Tg9949 mice.
Found at: doi:10.1371/journal.ppat.1000736.s011 (0.01 MB PDF)
Table S6 Attempted serial transmission of MoSP2 prions to
FVB mice.
Found at: doi:10.1371/journal.ppat.1000736.s012 (0.01 MB PDF)
Table S7 Attempted transmission of amyloid fibers to FVB
mice.
Found at: doi:10.1371/journal.ppat.1000736.s013 (0.04 MB PDF)
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